ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 277 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,177 | -8.5% | 479,624 | +1.2% | 0.03% | -6.2% |
| Q2 2023 | $14,408 | -11.2% | 473,981 | +3.3% | 0.03% | -22.0% |
| Q1 2023 | $16,217 | -15.6% | 458,647 | -7.9% | 0.04% | -19.6% |
| Q4 2022 | $19,215 | -99.8% | 498,128 | +77.1% | 0.05% | +54.5% |
| Q3 2022 | $11,025,000 | +28.1% | 281,301 | +32.8% | 0.03% | +32.0% |
| Q2 2022 | $8,606,000 | +1.0% | 211,765 | -0.7% | 0.02% | +19.0% |
| Q1 2022 | $8,517,000 | +74.6% | 213,352 | +78.6% | 0.02% | +75.0% |
| Q4 2021 | $4,878,000 | +22.8% | 119,446 | +8.8% | 0.01% | +9.1% |
| Q3 2021 | $3,971,000 | -13.7% | 109,827 | -0.9% | 0.01% | -15.4% |
| Q2 2021 | $4,599,000 | -0.5% | 110,792 | +2.5% | 0.01% | -13.3% |
| Q1 2021 | $4,624,000 | +13.8% | 108,094 | +29.6% | 0.02% | 0.0% |
| Q4 2020 | $4,065,000 | +297.4% | 83,428 | +297.3% | 0.02% | +150.0% |
| Q2 2020 | $1,023,000 | – | 21,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |